Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Possible Protective Role of Silymarin Against Chemotherapy Induced Toxicities and Cognitive Impairment in Breast Cancer Patients

NCT05595109 is registered in ClinicalTrials.gov with Tanta University as lead sponsor.

NCT NCT05595109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05595109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Possible Protective Role of Silymarin Against Chemotherapy Induced Toxicities and Cognitive Impairment in Breast Cancer Patients
Lead sponsor
Tanta University
Phase
Phase 2/3
Overall status
Unknown status
Start date
October 28, 2022
Completion date
October 28, 2024
Enrollment
56 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cardiac toxicities, cognitive impairment, hepatic toxicity, peripheral neuropathy